Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

quote:

Eagle-57 schreef op 7 december 2017 11:28:

Oh oh Harrie, bijna op DH ingestapt..... ;-P

quote:

Harry Nik schreef op 7 december 2017 10:02:

Als de koers inderdaad weer gaat stijgen koop ik ook maximaal mezelf vol. Beter als elke dag geld verliezen...of bij een stijging eerst ug duizend verlies moeten goedmaken...

quote:

C200 schreef op 7 december 2017 10:06:

Koersdoelverhoging First Berlin Van 1,50 naar 1,70

First Berlin – Pharming Group NV Research Update (07/12/2017)
07 Dec 2017 By First Berlin Equity Research News
First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and increased the price target from EUR 1.50 to EUR 1.70.

Abstract
Several factors have conjoined to produce accelerating sales growth and a jump in the Pharming share price of over 260% since June. First, the sales force built up during H1/17 following the acquisition of full US Ruconest commercialisation rights in late 2016 reached full effectiveness during the third quarter. Second, an article in The Lancet highlighting Ruconests excellent phase II results in hereditary angioedema (HAE) prophylaxis was published a few weeks before the onset of a shortage of Shire's Cinryze - the market leader in this indication. Then, in September, Pharming announced plans to present an SBLA (Supplemental Biologics License Application) for Ruconest to the FDA for review with a view to expanding the drug's indication in HAE from acute attacks to prophylaxis. The SBLA, which was submitted last week, strengthens our confidence that Ruconest will be approved for HAE prophylaxis without a phase III trial and that first revenues in this indication will be generated in 2019. Q3/17 was a breakthrough quarter for Pharming. Revenue of €26.1m was 69% above Q1/17 and 72% above Q2/17 while EBIT at €8.5m was more than double the H1/17 figure of €4.2m. Management guidance for Q4/17 is for a "significant increase" in revenue relative to Q3/17 due in part to the Cinryze shortage. However, even assuming an end to the Cinryze shortage in 2018, we model 52.9% revenue growth in 2018 vs. 2017 based on Ruconest's newly raised profile on the US market, and its low side effect burden relative to competitors. We have raised our 2018 sales and EBIT forecasts by 52% and 130% respectively on our last study of 14 September and now see fair value for the stock at €1.70 (previously €1.50). We maintain our Buy recommendation.
Filed Under: Research

firstberlin.com/first-berlin-pharming...

quote:

husa schreef op 7 december 2017 11:37:

dat Ruconest zal worden goedgekeurd voor HAE-profylaxe zonder een fase III-studie en dat de eerste inkomsten in deze indicatie in 2019 zullen worden gegenereerd.

inkomsten HAE laten toch nog even op zich wachten.

quote:

Harry Nik schreef op 7 december 2017 11:37:

Ik zei tegen me vrouw het gaat met schokjes omhoog...euh..lang verhaal kort ik ben ff offline...

quote:

Harry Nik schreef op 7 december 2017 11:28:

[...]

Kap eens met zeiken..

quote:

jakhals schreef op 7 december 2017 11:38:

2e upswing is in de maak!

quote:

Harry Nik schreef op 7 december 2017 11:21:

Order geplaatst op 1,230...ja durf wel aan nu..